Treatment Strategies and Survival Outcomes of Patients with EGFR-mutated NSCLC and leptomeningeal metastasis

被引：0
|
作者：
Fan, Y. [1 ]
Wu, H. [1 ]
Chen, K. [1 ]
机构：
[1] Zhejiang Canc Hosp, Hangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Leptomeningeal metastases; EGFR TKI resistance; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-30
引用
收藏
页码：S652 / S652
页数：1
相关论文
共 50 条
  • [1] A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis
    Fang, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S422 - S422
  • [2] The efficacy and safety of furmonertinib in patients with advanced EGFR-mutated NSCLC and leptomeningeal metastases
    Han, Huan
    Tang, Hong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
    Jiang, Tao
    Xu, Xiaobo
    Chen, Xiaojuan
    Ding, Ning
    Hu, Qin
    Zhou, Caicun
    Hu, Jie
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (06) : 2514 - 2517
  • [4] Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis
    Kuiper, Justine L.
    Hendriks, Lizza E.
    van der Wekken, Anthonie J.
    de Langen, Adrianus J.
    Bahce, Idris
    Thunnissen, Erik
    Heideman, Danielle A. M.
    Berk, Yvonne
    Buijs, Ed J. M.
    Speel, Ernst-Jan M.
    Krouwels, Frans H.
    Smit, Hans J. M.
    Groen, Harry J. M.
    Dingemans, Anne-Marie C.
    Smit, Egbert F.
    [J]. LUNG CANCER, 2015, 89 (03) : 255 - 261
  • [5] A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib plus /- Brain Metastases
    Litt, I.
    Gibson, A.
    Dean, M.
    Elegbede, A.
    Bebb, G.
    Cheung, W.
    Pabani, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S232 - S232
  • [6] EGFR-mutated NSCLC: A roadmap to treatment sequences
    Girard, Nicolas
    [J]. MED, 2024, 5 (09): : 1044 - 1047
  • [7] Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
    Tsuboi, Masahiro
    Herbst, Roy S.
    John, Thomas
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu Thi
    Dechaphunkul, Arunee
    Kowalski, Dariusz
    Poole, Lynne
    Bolanos, Ana
    Rukazenkov, Yuri
    Wu, Yi-Long
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (02): : 137 - 147
  • [8] Clinical outcomes in Black patients with EGFR-mutated NSCLC treated with osimertinib
    Belani, Neel
    Rizwan, Farsha
    Hasler, Jill
    Bauman, Jessica
    Mitchell, Khadijah
    Borghaei, Hossein
    Bodor, Joseph N.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
  • [9] Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
    Mei-Mei Zheng
    Yang-Si Li
    Hai-Yan Tu
    Hao Sun
    Kai Yin
    Ben-Yuan Jiang
    Jin-Ji Yang
    Xu-Chao Zhang
    Qing Zhou
    Chong-Rui Xu
    Zhen Wang
    Hua-Jun Chen
    De-Xiang Zhou
    Yi-Long Wu
    [J]. BMC Medicine, 20
  • [10] Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
    Zheng, Mei-Mei
    Li, Yang-Si
    Tu, Hai-Yan
    Sun, Hao
    Yin, Kai
    Jiang, Ben-Yuan
    Yang, Jin-Ji
    Zhang, Xu-Chao
    Zhou, Qing
    Xu, Chong-Rui
    Wang, Zhen
    Chen, Hua-Jun
    Zhou, De-Xiang
    Wu, Yi-Long
    [J]. BMC MEDICINE, 2022, 20 (01)
12345